Lyra Therapeutics GAAP EPS of -$3.38 beats by $0.98 [Seeking Alpha]
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study [Yahoo! Finance]
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study